Aaron Weaver

Chief Commercial Officer

Aaron Weaver is Chief Commercial Officer of Molecule AG, a company applying decentralised-science models and tokenised intellectual property to fund early-stage biotech research. He leads commercial strategy and ecosystem development, connecting researchers, funders and biotech DAOs around new financing models for drug discovery. Before joining Molecule, he was a Senior Partner at Apeiron Investments, focusing on frontier-technology investments in biotech, longevity and mental health, and served as Investment Director at Frontier Acquisition Corp, a Nasdaq-listed special purpose acquisition company focused on longevity science. He has served on the boards of Rejuveron Life Sciences and Alto Neuroscience. He began his career in investment banking at Credit Suisse before qualifying as a lawyer at Allen & Overy in London.